News

Keyword Search

Year

Oct 14, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Oct. 14, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated

Oct 01, 2021

CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19

SEATTLE , Oct. 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, compared pacritinib/standard of care versus

Sep 28, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Sept. 28, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to fourteen new employees as equity inducement awards outside of the Company's Amended and

Sep 17, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Sept. 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to twenty-five new employees as equity inducement awards outside of the Company's Amended and

Sep 08, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to seventeen new employees as equity inducement awards outside of the Company's Amended and

Aug 26, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Aug. 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated

Aug 25, 2021

CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction

SEATTLE and TORONTO , Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty

Aug 24, 2021

CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

SEATTLE , Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and

Aug 05, 2021

CTI BioPharma Reports Second Quarter 2021 Financial Results

SEATTLE , Aug. 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2021 .

Jul 29, 2021

CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021

SEATTLE , July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021 , after the close of the U.S. financial markets.

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Investors

News

News

–

–

–

–